Dr.Β JohnΒ Maris
BS, MD
Giulio D'Angio Chair in Neuroblastoma Research
corporate_fareChildren's Hospital of Philadelphia, USA
John Maris
BS, MD
Dr. John M. Maris is an internationally recognised paediatric oncologist and physician-scientist at Children's Hospital of Philadelphia (CHOP), one of the leading paediatric cancer centres in the United States. He holds the Giulio D'Angio Chair in Neuroblastoma Research and is Professor of Pediatrics at the Perelman School of Medicine, University of Pennsylvania.
With more than three decades of focused work on neuroblastoma, Dr. Maris has dedicated his career to understanding why neuroblastoma develops, why some tumours resist standard treatment, and how genomic and immunotherapy discoveries can be translated into better therapies for children. His laboratory has contributed substantially to identifying neuroblastoma susceptibility genes and molecular drivers of the disease. He co-heads the CHOP Pediatric Cancer Dream Team and leads or participates in several early-phase clinical trials for refractory neuroblastoma. Google Scholar lists more than 66,000 citations to his published work. Dr. Maris has mentored more than 100 trainees across research and clinical disciplines throughout his career.
CancerFax can coordinate medical-report review and consultation support for international families seeking a paediatric oncology opinion from Dr. Maris at Children's Hospital of Philadelphia, subject to hospital availability and case acceptance.
Why Consider Dr. John M. Maris?
Families dealing with high-risk, relapsed, or refractory neuroblastoma seek Dr. Maris for his unparalleled depth in paediatric neuroblastoma research and his direct access to early-phase clinical trials at CHOP, one of the world's foremost paediatric cancer centres.
Areas of Specialisation
Expert paediatric oncology care focused on neuroblastoma, childhood solid tumours, and translational research-driven treatment strategies
Dr. Maris's clinical and research specialisations span neuroblastoma biology, precision therapeutics, paediatric cancer genetics, and immunotherapy. His work bridges bench science and bedside care, with a particular emphasis on children whose disease has not responded to standard treatment.
Neuroblastoma
Comprehensive evaluation and research-driven management of neuroblastoma, including high-risk and refractory cases.
- arrow_rightMultidisciplinary treatment planning for newly diagnosed high-risk disease
- arrow_rightGenomic profiling and biomarker-guided treatment selection
- arrow_rightAccess to early-phase clinical trials for eligible patients
- arrow_rightEvaluation for early-phase clinical trial eligibility
- arrow_rightPrecision therapeutics based on molecular and genetic disease profile
- arrow_rightResearch-informed second opinion for complex cases
Paediatric Cancer Genetics & Immunotherapy
Genomic-based risk assessment, susceptibility gene discovery, and immunotherapy target development for childhood cancers.
- arrow_rightFamily-based and genome-wide association approaches to neuroblastoma risk
- arrow_rightIdentification of molecular drivers and therapeutic targets
- arrow_rightPeptide-centric CAR T-cell therapy development for neuroblastoma
- arrow_rightAnti-GD2 antibody-based treatment research contributions
- arrow_rightRadiopharmaceutical therapy preclinical development including MABG approaches
Procedures & Clinical Approaches
Paediatric oncology services and research-led treatment pathways at Children's Hospital of Philadelphia
Dr. Maris's clinical work encompasses direct patient care, multidisciplinary treatment planning, early-phase trial participation, and precision therapeutics for neuroblastoma and other childhood solid cancers. Specific treatment availability should be confirmed with CHOP for each patient.
Paediatric Oncology Consultation
Medical OncologyComprehensive evaluation and treatment planning for children with neuroblastoma and other solid tumours.
Early-Phase Clinical Trials
Complex DiseaseAccess to novel investigational therapies for children with refractory or relapsed neuroblastoma through CHOP-led and collaborative early-phase trials.
Precision & Targeted Therapy Planning
Targeted TherapyGenomic and biomarker-driven treatment selection for neuroblastoma and related childhood cancers.
Second Opinion
Second OpinionExpert review of diagnosis, pathology, and treatment plan for families seeking a specialist neuroblastoma second opinion from CHOP.
Research & Publications
Major contributions to neuroblastoma biology, genetics, immunotherapy, and precision paediatric oncology
Dr. Maris is among the most cited paediatric oncology researchers globally, with over 66,000 citations recorded on Google Scholar. His work spans neuroblastoma susceptibility genetics, molecular pathogenesis, immunotherapy target discovery, CAR T-cell therapy development, and early-phase trial leadership.
Dr. Maris's full publication list is available on Google Scholar and PubMed. His laboratory continues to publish actively on neuroblastoma genetics, immunotherapy, and precision therapeutics.
Education & Training
Dr. Maris completed his undergraduate studies at Wheeling College, earned his MD at the University of Pennsylvania School of Medicine, and completed specialist training in paediatric haematology/oncology and cancer genetics entirely at Children's Hospital of Philadelphia.
Clinical Experience
Dr. Maris has spent his entire clinical and research career at Children's Hospital of Philadelphia, progressing from trainee to one of the most prominent paediatric cancer physician-scientists in the United States. He currently serves as Attending Physician, holds the Giulio D'Angio Chair in Neuroblastoma Research, and directs the Center for Childhood Cancer Research.
Languages & International
Dr. Maris consults in English. No other languages have been publicly confirmed from reviewed sources.
CancerFax can coordinate professional medical interpreter support for international patients consulting through Children's Hospital of Philadelphia.
CancerFax can coordinate professional medical interpreter support for international families when required.
How CancerFax Helps You Access Dr. John Maris
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. John Maris's team β with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history β prepared as a structured clinical summary for Dr. John Maris's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. John Maris before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. John Maris's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. John Maris's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. John Maris's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Dr. John M. Maris
Dr. Maris specialises in paediatric oncology with a primary focus on neuroblastoma and childhood solid cancers. Children's Hospital of Philadelphia lists neuroblastoma and childhood solid tumours as his core areas of clinical expertise, encompassing both newly diagnosed and refractory disease.
Dr. John M. Maris is an Attending Physician at Children's Hospital of Philadelphia (CHOP) in the United States, where he also holds the Giulio D'Angio Chair in Neuroblastoma Research and directs the Center for Childhood Cancer Research. He is additionally Professor of Pediatrics at the Perelman School of Medicine, University of Pennsylvania.
Children's Hospital of Philadelphia has pathways for new patient referrals and second opinions, including for international families. CancerFax can help coordinate medical-report preparation and submission to CHOP, subject to hospital availability and case acceptance. Families should confirm appointment eligibility directly with CHOP.
A second-opinion request for neuroblastoma or another childhood solid tumour can be submitted through CancerFax. You will need to provide pathology reports, imaging, treatment history, and any relevant genomic or biomarker results. The final consultation format and availability are subject to the doctor's schedule and CHOP's institutional policies.
Yes. Dr. Maris is an active clinical trial leader. His clinical practice includes caring for children with refractory neuroblastoma, often within early-phase clinical trials. He co-leads the Pediatric Cancer Dream Team and chairs the NCI Cancer Moonshot Pediatric Immunotherapy Discovery and Development Steering Committee. Trial eligibility must be assessed individually by the CHOP team.
Submit your child's medical reports through CancerFax. The CancerFax team will review the documents, prepare the case summary, and coordinate the next steps with Children's Hospital of Philadelphia, subject to availability and case-acceptance criteria. You can begin by uploading reports at cancerfax.com.
Connect with John Maris Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.